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Abstract
Background: Interleukin 1 beta (IL-1β) plays an important role in a number of chronic and acute
inflammatory diseases. To understand the role of IL-1β in disease processes and develop an in vivo
screening system for anti-inflammatory drugs, a transgenic mouse line was generated which
incorporated the transgene firefly luciferase gene driven by a 4.5-kb fragment of the human IL-1β
gene promoter. Luciferase gene expression was monitored in live mice under anesthesia using
bioluminescence imaging in a number of inflammatory disease models.
Results: In a LPS-induced sepsis model, dramatic increase in luciferase activity was observed in the
mice. This transgene induction was time dependent and correlated with an increase of endogenous
IL-1β mRNA and pro-IL-1β protein levels in the mice. In a zymosan-induced arthritis model and an
oxazolone-induced skin hypersensitivity reaction model, luciferase expression was locally induced
in the zymosan injected knee joint and in the ear with oxazolone application, respectively.
Dexamethasone suppressed the expression of luciferase gene both in the acute sepsis model and
in the acute arthritis model.
Conclusion: Our data suggest that the transgenic mice model could be used to study
transcriptional regulation of the IL-1β gene expression in the inflammatory process and evaluation
the effect of anti-inflammatory drug in vivo.
Background
The cytokine interleukin 1 beta (IL-1β) is a potent media-
tor in response to infection and injury [1]. It is produced
mainly by blood monocytes, but also by macrophages,
dendritic cells and a variety of other cells in the body [2,3].
A minute amount of IL-1β in vivo can evoke fever, hypo-
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production of cytokines which in turn induce various
inflammatory and immune responses.
Increased IL-1β production has been reported in patients
with various infections, inflammation, trauma (surgery),
ischemic diseases, tumors, intravascular coagulation,
autoimmune disorders, UV radiation, graft-versus-host
disease, transplant rejection, and in healthy subjects after
strenuous exercise [4,5]. An increasing IL-1β production
was observed in patients with Alzheimer's disease and a
possible role for IL-1β in the release of the amyloid pre-
cursor protein was proposed [6]. Significant elevations of
plasma IL-1β have been detected in healthy humans
injected with lipopolysaccharide (LPS) and in patients
with septic shock and burns [7]. Correlations have been
found between plasma IL-1β levels and severity of acute
attacks of rheumatoid arthritis, thermal burns, and mor-
tality in septic shock [8]. Agents that reduce the produc-
tion and activity of IL-1β are likely to have an impact on
clinical applications. In fact, IL-1Ra, a blocker of IL-1β
transduction, has been administered to patients with sep-
tic shock, rheumatoid arthritis, steroid resistant graft-ver-
sus-host disease, AML, CML and so on [8-11].
Development of a method to monitor IL-1β gene pro-
moter activity in vivo will facilitate its use in the study of
related diseases and preclinical evaluation of anti-inflam-
matory drugs. For this purpose, in this paper, we have
established a transgenic mouse model using the human
IL-1β gene promoter [12] to direct the expression of luci-
ferase reporter gene. When combining with the approach
of "biophotonic" imaging using a highly light-sensitive
camera system [13-15], this model allows us to non-inva-
sively study the transcriptional activity of IL-1β gene pro-
moter in real time. Our data indicate that human IL-1β
gene promoter functions in transgenic mice and this
model can be used to study transcriptional regulation of
the IL-1β gene expression in the inflammatory process
and evaluate the effects of anti-inflammatory agents on IL-
1β gene induction in vivo.
Results
Founder screening and molecular characterization
The plasmid used for construction of transgenic mice was
illustrated in Fig. 1A. Transgenic founders is identified by
PCR detection of luciferase gene (using the primer pair
marked in Fig. 1A) in tail-clip DNA (Fig. 1B). Four
founder mice were obtained and crossed to BALB/c mice
for five generations to generate progeny for further exper-
iments.
Induction of luciferase expression in cHS4I-hIL-1βP-Luc 
transgenic mice by LPS
The progenies of cHS4I-hIL-1βP-Luc transgenic founders
were screened for luciferase expression in response to LPS
as described in materials and methods. All transgenic lines
showed robust inducible luciferase activity in the whole
body after LPS treatment while injection with saline did
not induce luciferase expression. One line named BALB/
cTg(cHS4I-hIL-1βP-Luc)Xen had the highest LPS-induced
luciferase expression (Fig. 2) and was selected for further
studies. In these mice, luciferase activity was detectable 1
h (n = 3/group, p > 0.05 in males compared with the base-
line level, p < 0.01 in females compared with the baseline
level) after LPS treatment all over the body and relatively
higher expression levels were seen at the position of liver,
intestine and lungs. The expression signal peaked at 3 h (n
= 3/group, p < 0.001 in males and females compared with
the baseline level, respectively) after treatment and then
gradually declined; by 168 h (n = 3/group, p > 0.05 in
males compared with the baseline level, p < 0.01 in
females compared with the baseline level) the signal had
returned to the baseline level (Fig. 2A, B). As quantified by
the LivingImage software, both male and female mice
showed significant LPS-induced luciferase signal above
the baseline level from 1 to 72 h after treatment, and the
kinetics and magnitude of the signals were similar in the
two sexes (Fig. 2C). At the peak, the luciferase signal was
induced by 7–8 fold in both sexes. In another experiment,
no significant difference in LPS-induced luciferase expres-
sion was found among mice aged from 2 to 7 months
(data not shown).
Expression of luciferase was induced in parallel with 
mouse endogenous IL-1β in multiple tissues after LPS 
treatment
To confirm the in vivo activity data observed by live imag-
ing, in another set of experiments, luciferase activity was
Schematic diagram of IL-1β-luc reporter system used for microinjectionFigure 1
Schematic diagram of IL-1β-luc reporter system used 
for microinjection. (A) The cHS4I-hIL-1βP-Luc transgene 
was constructed by inserting a 4.5-kb 5' flanking promoter 
region of the human IL-1β gene in front of firefly luciferase 
cDNA. (B) Genotyping by PCR yielded a 600-bp fragment. 
PCR products were run on a 1% agarose gel. Lane 1 was a 
DL 2,000 DNA ladder, lane 2 was the product from a wild-
type CBA control, lane 3 was the product from a wild-type 
C57BL/6 control, lane 4 was the buffer for dissolving the 
genomic DNA, and lanes 5–8 were samples from cHS4I-hIL-
1βP-Luc heterozygous transgenic mice. P1: forward-luc 
primer, P2: reverse-luc primer.Page 2 of 9
(page number not for citation purposes)
BMC Immunology 2008, 9:49 http://www.biomedcentral.com/1471-2172/9/49detected ex vivo in dissected organs of cHS4I-hIL-1βP-Luc
female mice at 5 h after LPS injection (Fig. 3A). The luci-
ferase activity was significantly higher in the liver, lungs,
duodenum, kidneys, brain, and heart. As compared with
the saline treated mice, LPS treatment induced the luci-
ferase activity by 11-fold in the liver, 19.6-fold in the
lungs, 21-fold in the duodenum, 10-fold in the kidneys,
5-fold in the brain, 4.5-fold in the heart, 5.5-fold in the
stomach, 2.7-fold in the thymus, and 1.5-fold in the
spleen (Fig. 3B), which was consistent with the in vivo
results at 5 h in Fig. 2B.
The LPS-induced expression of mouse endogenous IL-1β
mRNA was evaluated by real-time RT-PCR (Fig. 3C). In a
large degree in parallel with that of the induced luciferase
expression, LPS treatment increased endogenous IL-1β
mRNA expression by 15.6-fold in the liver, 9.5-fold in the
lungs, 4.7-fold in the kidneys, 9-fold in the brain, 5-fold
in the heart, 2.5-fold in the stomach, 12.7-fold in the thy-
mus, 4.2-fold in the spleen, and 1.3-fold in the duode-
num. Western Blot analysis showed that LPS significantly
induced the expression of pro-IL-1β protein in lung,
spleen, and thymus of mice (Fig. 3D).
Luciferase expression in cHS4I-hIL-1βP-Luc transgenic 
mice was inducible during acute arthritis
The inducibility of IL-1β gene expression during acute
inflammatory arthritis was studied using the cHS4I-hIL-
1βP-Luc transgenic mouse model. Intra-articular injection
of zymosan into the right knee joint of cHS4I-hIL-1βP-Luc
mice caused a local induction of luciferase signal which
was detectable at 2 h, peaked at 8 h, started to decline at
24 h and was still detectable at 96 h after the local treat-
ment (Fig. 4A, B). The luciferase signal at the zymosan-
injected right knee joints were 3.1-, 7.6-, 6.9-, and 2.8-fold
of the base level at 3, 8, 24, and 96 h, respectively (Fig.
4B). The saline injected left knees showed slight increase
in luciferase signal, possibly caused by a systemic
response to zymosan administration and/or the lesion at
the injection site. The induction of luciferase signal corre-
lated with an increase of knee joint volume, as measured
across lateral/medial axis and the anterior/posterior axis
of the knee joints (results not shown).
Luciferase expression was inducible during CHS reaction
In a third model of inflammatory disease, cHS4I-hIL-1βP-
Luc female mice were sensitized with oxazolone and top-
Induction of hIL-1βP-driven luciferase expression in IL-1β-luc transgenic mice by LPSFig r  2
Induction of hIL-1βP-driven luciferase expression in 
IL-1β-luc transgenic mice by LPS. Dorsal and ventral 
views of a representative mouse are depicted for male (A) 
and female (B) mice. The color overlay on the images repre-
sents the photons/sec/cm2/steradian (p/s/cm2/sr), as indicated 
by the color scale next to the images. (C) Quantification of 
luciferase activity (photons/sec) of the whole body with the 
LivingImage software. Data presented are group means of 3 
mice ± standard errors.
hIL-1βP-driven luciferase expression is induced in multiple tissues of IL-1β-luc t nsg nic mice after LPS treat entFig re 3
hIL-1βP-driven luciferase expression is induced in 
multiple tissues of IL-1β-luc transgenic mice after 
LPS treatment. (A) Female cHS4I-hIL-1βP-Luc mice (n = 
3) were treated with LPS (3 mg/kg). At 5 h after LPS injec-
tion, mice were sacrificed and selected organs were rapidly 
harvested and homogenized for luciferase activity measure-
ment with a luminometer. Saline-treated mice were used as 
controls. (B) Fold induction of the luciferase expression in 
the selected organs. Degree of change in gene expression is 
based on the expression level of the saline-treated mice. All 
values were expressed as mean ± SE. (C) Quantification-RT-
PCR analysis for IL-1β gene expression in female mice. The 
mRNA levels of IL-1β gene expression in the selected organs 
of LPS-treated mice were quantified using real-time RT-PCR 
with Evagreen detection at 5 h after treatment. Degree of 
change in gene expression is based on the expression level of 
the saline-treated mice. All values were expressed as mean ± 
SE (n = 3/group). (D) Western blot for the presence of pro-
IL-1β protein in the spleen, thymus and lung at 5 h following 
treatment with saline or LPS.Page 3 of 9
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later. Oxazolone challenge induced luciferase expression
in the right ears at the level of 2.6 fold of the base level at
day 1 after challenge (Fig. 5B). A weak induction of luci-
ferase expression was also observed in the vehicle injected
left ear. Induction of luciferase expression correlated with
increase in ear thickness (Fig. 5C).
Dexamethasone inhibited the induction of luciferase 
expression
Dexamethasone, a synthetic glucocorticoid, has been well
characterized for its ability to inhibit IL-1β production. A
major mechanism is that dexamethasone inhibits IκB deg-
radation and therefore suppresses IL-1β gene transcrip-
tion promoted by NF-κB signaling pathway [16,17]. Male
cHS4I-hIL-1βP-Luc mice were cotreated with LPS and dex-
amethasone (3 mg/kg i.p.) or LPS and saline. The dexam-
ethasone cotreated mice had 51.5% lower induced
luciferase expression as compared with the saline
cotreated mice (Fig. 6A, B). Similarly, dexamethasone
inhibited the induced luciferase expression in the
zymosan induced acute arthritis model (Fig. 6C, D).
Discussion
We have generated a cHS4I-hIL-1βP-Luc transgenic mouse
model for monitoring hIL-1β gene transcriptional activity
during inflammation. Using an in vivo bioluminescence
imaging system, we demonstrated that luciferase signals
in the cHS4I-hIL-1βP-Luc transgenic mice were dramati-
cally induced in the whole body (especially in liver, duo-
denum, lung, kidneys, stomach, brain, and thymus)
following treatment with LPS. Direct quantification of
luciferase signals using the LivingImage software yielded
data comparable to those obtained by the conventional
luminometer assay performed on excised and homoge-
nized tissues. In an arthritis and a CHS reaction model,
luciferase signals were induced locally in the treated area.
Dexamethasone, a well known blocker of IL-1β produc-
tion [16-18], suppressed the induced expression of luci-
ferase in transgenic mice in these inflammation models.
These data indicate that cHS4I-hIL-1βP-Luc mice are use-
ful as a sensitive and convenient model for monitoring IL-
1β gene expression during the disease process in a broad
range of inflammatory conditions and for evaluating the
effects of anti-inflammatory drugs.
Monitoring hIL-1βP-driven luciferase expression in IL-1β-luc transgenic mice during zymosan-induced acute arthritisFigur  4
Monitoring hIL-1βP-driven luciferase expression in 
IL-1β-luc transgenic mice during zymosan-induced 
acute arthritis. (A) Female cHS4I-hIL-1βP-Luc mice (n = 3/
group). were injected with zymosan (300 μg/knee) into the 
right rear knee joint, and vehicle (5% glucose in PBS) into the 
left rear knee joint. The mice were imaged at 0, 1, 3, 4, 6, 8, 
24, 30, 48, 72, and 96 h following injection. The color overlay 
on the images represents the photons/sec/cm2/steradian (p/s/
cm2/sr), as indicated by the color scale next to the images. 
(B) Quantification of luciferase activity (photons/sec) of the 
knee region by the LivingImage software. Data presented 
were mean ± SE.
hIL-1βP-driven luciferase expression in IL-1β-luc transgenic mice in an oxazolone-CHS modelFigure 5
hIL-1βP-driven luciferase expression in IL-1β-luc 
transgenic mice in an oxazolone-CHS model. (A) 
Female cHS4I-hIL-1βP-Luc mice (n = 3) are sensitized with 
oxazolone on day -6. On day 0, the right ears were chal-
lenged with oxazolone and the left ears were treated with 
vehicle. Imaging analysis was performed on day – 6, 0, 1, and 
30. (B) Quantification of luciferase expression (photons/sec) 
in all the ears with LivingImage software. Data were pre-
sented as mean ± SE. (C) Ear thickness was measured on day 
– 6, 0, 1, and 30 with a micrometer. Data represent mean ± 
SE. *** indicate significant differences at p < 0.001. p/s/cm2/sr: 
photons/sec/cm2/steradian.Page 4 of 9
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sion rely mostly on either measuring circulating levels of
IL-1β in the serum or mRNA expression in tissues. Com-
pared with these methods, the approach reported in this
study is convenient and sensitive, and more importantly,
with this approach the kinetics as well as the anatomical
location of IL-1β gene expression can be conveniently
studied and use a minimal number of animals. This is
extraordinarily useful in monitoring both systematic and
local inflammation, such as sepsis, arthritis, and chemi-
cal-induced skin toxicity.
The pattern of LPS-induced luciferase expression in trans-
genic mice was generally in agreement with the endog-
enous murine IL-1β mRNA expression. However, the fold
of increase did not match exactly between luciferase activ-
ity and endogenous IL-1β mRNA. This might be explained
by the facts that the promoter for the luciferase is from
human and IL-1β mRNA level and protein level are often
not in linear correlation. In addition, translational regula-
tion of IL-1β mRNA and luciferase mRNA, as well as post-
translational regulation of IL-1β protein and luciferase
protein, may also be different. So it should be note that
the signal of luciferase in the reporter mice may be not
consist with the IL-1β protein level since the regulation of
IL-1β protein translational and posttranslational process
is rather complex in vivo[19]. However, these differences
do not affect the application of our transgenic model in
inflammation research to monitor the mRNA level of IL-
1β. In the cHS4I-hIL-1βP-Luc transgenic mice described
here, there were no clear gender differences in both base-
line of luciferase signals and response to LPS where nearly
identical kinetics and signal intensity were observed. This
result is in agreement with the results reported previously
[20].
IL-1β have been found in the synovial fluid recovered
from inflamed joints of rheumatoid arthritis patients [21].
We clearly demonstrated that local administration of
zymosan into knee joints triggered induction of luciferase
expression in the joints, which correlated with the
increases in both IL-1β mRNA and protein in zymosan-
treated knee joint tissue reported earlier [22]. It is believed
that locally synthesized IL-1β by synovial cells in inflamed
joints plays a key role in the pathogenesis of rheumatoid
arthritis, and IL-1β can be used as a marker for evaluating
the efficacy of therapeutics for rheumatoid arthritis.
Luciferase expression was also clearly induced in the ear of
the transgenic mice in a CHS model. Contact hypersensi-
tivity is a two-phase process. The induction phase begins
on initial epicutaneous application of a hapten (low-
molecular-weight chemical), resulting in activation and
rapid lymphocyte proliferation. The challenge or elicita-
tion phase occurs when sensitized individuals are re-
exposed to the sensitizing antigen. This local CHS reaction
is characterized by infiltrating T lymphocytes, macro-
phages, and neutrophils. It has been reported that mice
with oxazolone treatment in the ear showed ear swelling
and increased expression levels of IL-1β, IL-4, IL-18 and
GM-CSF [23,24]. In line with these reports, we showed
that luciferase expression was induced in the ear of the
transgenic mice at day 1 after oxazolone challenge and the
expression level correlated with the increase in ear thick-
ness.
The regulatory region for human IL-1β gene expression
was found to be distributed over several thousand basepa-
irs upstream and a few basepairs downstream from the
transcriptional start site [25]. There are two independent
Dexamethasone inhibits hIL-1βP-driven luciferase expression in IL-1β-luc transgenic mice in the LPS and zymosan induced flam ation mod lsFigure 6
Dexamethasone inhibits hIL-1βP-driven luciferase 
expression in IL-1β-luc transgenic mice in the LPS 
and zymosan induced inflammation models. (A) Dex-
amethasone inhibits LPS-induced hIL-1βP-driven luciferase 
expression. Male cHS4I-hIL-1βP-Luc mice (n = 3/group) were 
cotreated with vehicle or dexamethasone (3 mg/kg) during 
the LPS (3 mg/kg) injection. All the mice were imaged at 0 
and 5 h after LPS injection. (B) Quantification of luciferase 
activity (photons/sec) with the LivingImage software. Data 
presented were mean ± SE. (C) Dexamethasone inhibits hIL-
1βP-driven luciferase expression during zymosan induced 
acute arthritis. Female cHS4I-hIL-1βP-Luc mice (n = 3/group) 
were cotreated with vehicle or dexamethasone (50 μg/
mouse) during the administration of zymosan (300 μg/
mouse). All the mice were imaged at 0 and 4 h after zymosan 
injection. (D) Quantification of luciferase activity (photons/
sec) of the articular region of the acute arthritis mice with 
the LivingImage software. Data presented were mean ± SE. 
*** indicate significant differences at p < 0.001. p/s/cm2/sr: 
photons/sec/cm2/steradian.Page 5 of 9
(page number not for citation purposes)
BMC Immunology 2008, 9:49 http://www.biomedcentral.com/1471-2172/9/49enhancer regions, -2782 to -2729 and -2896 to -2846 that
appear to act cooperatively [26]. The latter contains a
cAMP response element, whereas the former is a compos-
ite cAMP response element (NFIL-6) that is responsive to
LPS. The 80-bp fragment (-2800 to -2720) is required for
transcription and contains, in addition to a cAMP
response element, an NF-κB-like binding site. Activating
protein-l (AP-l) sites also participate in endotoxin-
induced IL-1β gene expression. Proximal promoter ele-
ments have also been identified between -131 and +14
[26]. Sequences in this region contain binding sites for the
novel nuclear factor NFβA [27], which appears to be sim-
ilar to nuclear factors termed NFβl and NFβ2 [26]. This
proximal promoter is required for maximal IL-1β gene
expression. The nucleotide binding sequences of NFβA are
found to be identical to those of the transcription factor
Spi-1/PU.1 [28,29], a well-established NF in cells of mye-
loid and monocyte lineage [30]. The requirement for Spi-
1/PU.1 for IL-1β gene expression imparts its tissue specif-
icity. Human blood monocytes, which constitutively
express Spi-l/PU.1, are exquisitely sensitive to LPS induci-
ble IL-1β gene expression. In our case, the promoter
region used for driving luciferase expression in the trans-
genic mice is 4.5-kb long which contains all the cis-ele-
ments discussed above. The chicken HS4 insulator
(cHS4I) upstream of the hIL-1βP may eliminate the trans-
genic chromosomal insertion site effect on transgene
expression[31]. Therefore, the expression of the luciferase
gene in the transgenic mice was expected to reflect the nat-
ural pattern of IL-1β gene expression.
Bioluminescence imaging techniques have been used to
study the expression of several inflammatory factors in
reporter mice, such as NF-κB-binding cis elements[13,15],
the inducible NO synthase gene(iNOS)[32], the vascular
endothelial growth factor-2 (VEGFR2)[33]. These reporter
systems can be successfully used to monitor and quantify
different inflammatory processes in vivo. Together with
our model in this paper, we believe these reporter mice
systems will facilitate us a better understanding of the
molecular mechanism of different diseases.
Conclusion
The cHS4I-hIL-1βP-Luc transgenic mouse, with its IL-1β
promoter driven luciferase expression, is able to provide
information about anatomical sites of IL-1β expression in
an inflammatory process. The induction was observed in
the whole body (especial in liver, lungs, and duodenum)
in a LPS-sepsis model, and was restricted to the treated
joints and ears in a zymosan-arthritis model and in an
oxazolone-CHS model, respectively. Treatment with dex-
amethasone, a proven IL-1β expression blocker, signifi-
cantly suppressed LPS- or zymosan-induced IL-1β
promoter-driven luciferase expression. As IL-1β induction
is featured in the pathogenesis of a number of acute and
chronic inflammatory diseases, the cHS4I-hIL-1βP-Luc
mouse is a useful tool not only for tracking various
inflammatory processes in vivo, but also for testing the
efficacies of therapeutic compounds that are targeted to
inflammatory diseases, especially those that involve
induction of IL-1β expression.
Methods
Reagents
Bacterial LPS (from Escherichia Coli Serotype 0127:B8),
zymosan A (a cell wall preparation from Saccharomyces
cerevisiae), dexamethasone and oxazolone were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). Luci-
ferin (Biosyth, Basel, Switzerland) was dissolved in PBS at
15 mg/ml and stored at -20°C.
Generation of cHS4I-hIL-1βP-Luc transgenic mice
A 4.5-kb Kpn I-Bgl II fragment of human IL-1β gene pro-
moter (hIL-1βP) was isolated from human genomic DNA
by PCR amplification according to the literature [12]. The
promoter fragment was verified by DNA sequencing and
cloned into the polylinker sites Kpn I and Bgl II of pGL3-
Basic (Promega) to direct the expression of luciferase
reporter gene (hIL-1βP-Luc). The resulting plasmid was
named as pGL3-hIL-1βP-Luc. In order to eliminate the
transgenic chromosomal insertion site effect on transgene
expression[31], the Not I-Kpn I fragment of the chicken
HS4 insulator (cHS4I) was cloned into the Not I and Kpn
I sites upstream to hIL-1βP. Then, the constructed cHS4I-
hIL-1βP-Luc cassette was cut and subcloned into the Apa I
and Sal I sites of plasmid pGFP-1. The cHS4I-hIL-1βP-Luc
transgenic cassette (Fig. 1A) was cut out by Apa I and Mlu
I, and used to generate transgenic mice in the C57XCBA
background by standard microinjection techniques. The
transgenic mice were bred to BALB/c for 5 generations
before testing. All animals were housed in a specific path-
ogen-free environment in accordance with institutional
guidelines for animal care. Animal handling was per-
formed in accordance with institutional guidelines and
approved by the local institutional animal care and use
committee.
Genotyping of cHS4I-hIL-1βP-Luc transgene in mice
Transgenic founders and their offspring were identified by
PCR using the forward-luc (5' TTCCGCCCTTCTT-
GGCCTTTATGA 3') and reverse-luc (5' CAGCTATTCT-
GATTACACCCGAGG 3') primers specific for luciferase
gene.
In vivo imaging
In vivo bioluminescent imaging was performed using an
IVIS imaging system (Xenogen, Alameda, CA) as previ-
ously described. 150 ul sodium salt luciferin (dissolved in
PBS) was injected into the intraperitoneal cavity at a dose
of 150 mg/ml. Mice were anesthetized with isoflurane/Page 6 of 9
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ferin injection, mice were imaged for 1 to 5 min. Photons
emitted from specific regions were quantified using a Liv-
ingImage software (Xenogen). In vivo luciferase activity
was presented in photons emitted per second.
Functional screening of cHS4I-hIL-1βP-Luc transgenic lines
For primary functional screening of transgenic lines, the
luciferase gene PCR positive mice were imaged for expres-
sion of the luciferase transgene without any treatment or
at 5 h after LPS injection at the does of 3.0 mg/kg. The cri-
teria used for screening available transgenic lines were: (1)
lower basal luciferase expression in normal status and (2)
higher induced luciferase expression in whole body after
LPS injection.
Acute septic shock model by intraperitoneal LPS injection
The acute septic shock model was produced by i.p. injec-
tion of LPS (3.0 mg/kg) into cHS4I-hIL-1βP-Luc trans-
genic mice at the age of 2–3 mo. Control mice were
injected with saline. At selected time points after the treat-
ment, mice were i.p. injected with luciferin and imaged 12
min later with the IVIS imaging system described above.
To test the effect of dexamethasone on LPS-triggered luci-
ferase expression, male mice were cotreated with dexame-
thasone and LPS, and the control mice were injected with
saline and LPS. The luciferase signal was monitored
through imaging.
Acute arthritis model by intra-articular administration of 
zymosan
Zymosan A was suspended in sterile saline containing 5%
glucose at a concentration of 30 mg/ml. Female cHS4I-
hIL-1βP-Luc mice at the age of 2–3 mo were anesthetized
with isoflurane. Then the hind legs of mice were shaved
and the skin was sterilized with 70% ethanol. The right
knee tendon was exposed and 10 μl of zymosan A suspen-
sion was intra-articularly injected through the tendon
with a 25-gauge needle. The left rear knees of the same
mice were intra-articularly injected with 5% glucose in
saline (sham control). Mice were imaged at selected time
points after the injection. Separately, mice were pretreated
with dexamethasone (50 μg/mouse i.p.) half hour before
the zymosan administration, and the luciferase signal was
monitored through imaging.
Induction of contact hypersensitivity (CHS) reaction
Female cHS4I-hIL-1βP-Luc mice, 3–6 mo of age, were
shaved in the thorax area and treated topically with 50 μl
of 2% oxazolone solution (in acetone/olive oil (4/1, vol/
vol)). Six days after sensitization, the right ears were chal-
lenged by topical application of 10 μl of 1% oxazolone
solution, and the left ears were treated with vehicle (ace-
tone/olive oil, 4:1 vol/vol) alone. The extent of inflamma-
tion was assessed by measuring ear thickness with a
micrometer. Bioluminescent images were collected on the
day of sensitization (day -6), the day of challenge (day 0),
and at day 1 and 30 after treatment.
Luciferase activity assay in vitro
Luciferase activity was assayed using the Luciferase Assay
System (Promega) on a Luminometer (Lumat LB9507,
EG&G, Berthold, Germany).
Total RNA isolation
Female cHS4I-hIL-1βP-Luc mice, 3–6 mo of age, were
treated with i.p. injection of LPS (3.0 mg/kg). Control
mice were injected with saline. After 5 h, total RNA was
isolated from selected mouse tissues using TRIZOL (Invit-
rogen, Paisley, Scotland, UK) according to the manufac-
turer's instruction and the extracted RNAs were kept at -
80°C prior to use.
Real-time reverse transcription-polymerase chain reaction 
(real time RT-PCR)
Two μg of the RNA samples isolated from the LPS-treated
female cHS4I-hIL-1βP-Luc mice was reverse-transcribed
into cDNA using M-MLV reverse transcriptase (Promega)
in a final reaction volume of 25 μl. For real time PCR
amplification, 0.5 μl of cDNA per reaction and 0.2 μM
primer sets were used. Reaction conditions were as fol-
lows: 94°C/4 min; 51 cycles of 94°C/30 s, 60°C/30 s,
72°C/30 s; and 72°C/10 min. Evagreen used for detecting
PCR products was purchased from Molecular Probes
(Gentaurer, Brussels, Belgium). Amplification and detec-
tion of Evagreen were performed with RG-3000 Real Time
Thermal Cycler (Corbett. Research, Sydney, Australia).
The expression of the mRNA for the murine β-actin gene
was used as a reference to normalize expression levels. All
data were expressed relative to β-actin to compensate for
any difference in sample loading, and all experiments
were performed in triplicates. Data were obtained as
threshold cycle (Ct) values (PCR cycle numbers at which
fluorescence was threshold) using Rotor-Gene Real-Time
Analysis Software 6.0 and used to calculate ΔCT values
(ΔCT is the Ct of the target gene subtracted from the Ct of
the housekeeping gene). Fold changes relative to saline
controls were determined by the 2-ΔΔCT method.
Primers for real time PCR were synthesized as the
sequences listed below (Sangon, Shanghai, China). The
forward murine IL-1β primer used was 5' AAGGAGAAC-
CAAGCAACGACAAAA 3', the reverse murine IL-1β
primer used was 5' TGGGGAACTCTGCAGACTCAAACT
3'. The forward murine β-actin primer used was 5' CCTG-
TATGCCTCTGGTCGTA 3', the reverse murine β-actin
primer used was 5' CCATCTCCTGCTCGAAGTCT 3'.
Western blot analysis of mIL-1β and luciferase activity 
assay in tissues
Mouse tissues were removed and homogenized in 3 vol-
umes of phosphate buffered saline (PBS) containing aPage 7 of 9
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anapolis, IN, USA) and lysed with passive lysis buffer
(Promega). After centrifugation at 14,000 rpm for 10 min
at 4°C, the supernatant was collected. Luciferase activity
was measured using a luminometer and the Luciferase
Assay System (Promega). Protein concentration in lysate
was estimated by Bradford reagent (Sangon, Shanghai,
China). For Western blot analysis, equal amounts of pro-
teins (120 μg) were loaded onto SDS-PAGE gels. After
transfer, the membrane was probed with a specific anti-
mIL-1β rabbit polyclonal Ab (Chemicon International,
Temecula, CA, USA). The blots were developed using the
ECL Plus Western Blotting Detection System (Amersham
Biosciences, Piscataway, NJ, USA).
Statistics
All data are expressed as means ± SE. The data were ana-
lyzed by one-way ANOVA. A P value of less than 0.05 was
considered significant.
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